Cargando…

Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients

Despite the efficacy of decitabine to myelodysplastic syndrome (MDS), there is a wide range of responses, and no definite predictive marker has been identified. This study aimed to describe the efficacy of decitabine and to identify potential predictors of response and survival in patients with MDS....

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Hyun Ae, Maeng, Chi Hoon, Kim, Moonjin, Kim, Sungmin, Jung, Chul Won, Jang, Jun Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599296/
https://www.ncbi.nlm.nih.gov/pubmed/25938546